Stocks directory

1530.HK

3SBIO

HKEXHealthcareBiotechnology

HK$18.52

+0.11%

2026-06-01

About 3SBIO

3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia. It also provides EPIAO for indications, such as the treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and the reduction of allogeneic blood transfusion in surgery patients; and Yisaipu, a TNF-a inhibitor product for rheumatoid arthritis, ankylosing spondylitis, and psoriasis indications. In addition, the company offers Cipterbin, an anti-HER2 mAb for treatment of HER2-positive metastatic breast cancer in combination with chemotherapy; and Mandi, a minoxidil tincture for androgenetic alopecia and alopecia areata. Further, it develops 608, an anti-IL-17A mAb; SSS20 for patients with ITP and severe Aplastic Anemia; SSS06 for the treatment of adult dialysis patients undergoing erythropoietin therapy with a biweekly dosing interval; 613, for the treatment of acute gouty arthritis; 611, an anti-IL-4R a mAb; and 601A, an anti-VEGF mAb. Additionally, the company is involved in manufacture and sale of pharmaceutical drugs; business management; provision of technical services, investment advisory services, financial services, sports services, clinic services, technology services, and agricultural services; retail of pharmaceuticals; and enterprise management consulting. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Key Fundamentals

P/E Ratio

5.65

Forward P/E

14.46

EPS (TTM)

HK$3.95

ROE

37.5%

Revenue Growth (YoY)

182.7%

Profit Margin

47.9%

Debt/Equity

8.60

Dividend Yield

1.1%

Price/Book

1.78

Beta

0.56

Market Cap

HK$55.81B

Avg Volume (10D)

25.2M

Recent Breakout Signals

Near-Breakout WatchD1
2025-11-18
Momentum BreakoutD1
2025-11-03
Near-Breakout WatchD1
2025-10-31
Near-Breakout WatchD1
2025-06-17
Momentum BreakoutD1
2025-06-09
Ceiling BreakoutD1
2025-06-09
Near-Breakout WatchD1
2025-05-21

Recent Price Range (60 Days)

60D High

HK$26.44

60D Low

HK$17.05

Avg Volume

33.3M

Latest Close

HK$18.52

Get breakout alerts for 1530.HK

Sign up for Breakout Scanner to receive daily notifications when 1530.HK triggers breakout signals. Build custom AI screeners and backtest strategies.

Start Free Trial

7-day free trial.

3SBIO (1530.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 1530.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 1530.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.